TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16996833
Drug: Half-dose TNK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose TNK with abciximab and reduced-dose UFH
Study: 12679443
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dosage of 0.067 mg/kg.d until attainment of adult height
Study: 11782853
Drug: Metoprolol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol IR 50 mg 3 times daily
Study: 12818732
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL 100 mg once daily
Study: 24247812
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL 200 mg once daily
Study: 9386657
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and Ibuprofen (both treatments)
Study: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine (FPZ) 20 mg/day
Study: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine (FPZ) 80 mg/day
Study: 7904762
Drug: Fluphenazine (FPZ)
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine (FPZ) 20 mg/day (open phase)
Study: 29148929
Drug: Alcohol-Wise (version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-Wise (version 4.0, 3rd Millennium Classrooms) administered prior to first semester
Study: 21346067
Drug: MRrhTSH 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRrhTSH 0.01 mg (group B, n = 30)
Study: 21346067
Drug: MRrhTSH 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRrhTSH 0.03 mg (group C, n = 33)
Study: 14636819
Drug: morphine 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 18 mg/70 kg intramuscular
Study: 14636819
Drug: morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 10 mg/70 kg intravenous
Study: 14636819
Drug: hydromorphone 2
Normalized name: HYDROmorphone 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydromorphone 2 mg/70 kg intravenous
Study: 8840306
Drug: 0.5 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 micrograms/day oral calcitriol (calcitriol group, n = 8)
Study: 8840306
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day calcium carbonate (CaCO3 group, n = 10)
Study: 1729619
Drug: Topical 0.1
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1 percent tretinoin
Study: 3885699
Drug: Tiapamil (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (1.5 mg/kg intravenous bolus followed by 50 micrograms/kg/min infusion for 3 hours)
Study: 20018492
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin (16g/day)
Study: 20018492
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus dosing of piperacillin (4g every 6h)
Study: 16622039
Drug: 0.6 mg/h
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/h GTN for 1 week (n=17)
Study: 16622039
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=11)
Study: 6539224
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg codeine phosphate
Study: 6539224
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dextromethorphan hydrobromide
Study: 8830977
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan hydrobromide
Study: 23475835
Drug: Contact lens
Normalized name: contact lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact lens (CL) treatment
Study: 18972725
Drug: Three-combination needling
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-combination needling method (acupuncture, acupoint-injection, fire-needle therapy)
Study: 18972725
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and acupoint-injection (control group)
Study: 12642637
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Study: 10713746
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil supplementation (230 or 460 mg gamma‐linolenic acid per day for one week)
Study: 1314965
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (1500 a PPT-Units/d Mono-Embolex NM)
Study: 9531030
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU t.i.d.)
Study: 23913972
Drug: Asoprisnil (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil (a progesterone receptor modulator)
Study: 10101617
Drug: Exchanging drugs
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exchanging drugs or money for sex
Study: 7485711
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (4 mg/kg/day for three days with mefloquine 25 mg/kg on the second day)
Study: 7485711
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (20 mg of salt/kg initially then 10 mg/kg every 8 hr, followed by mefloquine 25 mg/kg)
Study: 31028737
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 4% articaine 1.8 mL
Study: 31028737
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 4% articaine 1.8 mL plus lingual injection of normal saline 0.4 mL
Study: 22018594
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg somatuline® (lanreotide) administered by a single subcutaneous injection for 2 weeks (Group B)
Study: 22018594
Drug: Paclitaxel 190
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 190 mg/m2 + carboplatin AUC=5.5 for up to 6 cycles (Group A, control group)
Study: 22018594
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg somatuline® autogel for 4 weeks (Group C)
Study: 17428109
Drug: Exenatide (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (subcutaneous, twice daily)
Study: 15522938
Drug: Cinacalcet (30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30-50 mg twice daily)
Study: 7486180
Drug: ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.1 mg/kg)
Study: 31106492
Drug: Transitioning to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitioning to very low nicotine content cigarettes plus nicotine patch
Study: 31106492
Drug: Reducing daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing daily cigarette consumption plus nicotine patch
Study: 21419770
Drug: peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2b (0.5 μg/kg/week)
Study: 19046169
Drug: Lactobacillus-containing vaginal
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus-containing vaginal tablets
Study: 17429915
Drug: rhEPO (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (250 IU/kg three times weekly, total of 15 times starting on day of life 5)
Study: 10867388
Drug: Integral valuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral valuation of treatment
Study: 6442856
Drug: Semi-elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-elemental diet (SED) with an osmolarity of 302 milliosmol per liter, low lactose content, and high lactalbumin hydrolysate (1 g/100 ml)
Study: 26604159
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) for 12 hours (loading dose 4g IV, maintenance 1g/hour)
Study: 26604159
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) for 24 hours (loading dose 4g IV, maintenance 1g/hour)
Study: 25740794
Drug: valACV 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: valACV 500 mg twice daily for 12 weeks
Study: 18619359
Drug: Bailing capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing capsule and medical gymnastics
Study: 18619359
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine (Control)
Study: 12568831
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of E2
Study: 12568831
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of E2 + 5 mg of medroxyprogesterone acetate (MPA)
Study: 8854286
Drug: Theophylline Lavipharm
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline Lavipharm (200 mg or 300 mg)
Study: 8854286
Drug: Theodur (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theodur (200 mg or 300 mg)
Study: 1607899
Drug: Weekly non-response
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly non-response
Study: 6092012
Drug: cefotaxime 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotaxime 3 x 2 g
Study: 6092012
Drug: lamoxactam 3
Normalized name: Lamoxactam
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lamoxactam 3 x 2 g
Study: 6092012
Drug: cefmenoxime 3
Normalized name: cefmenoxime
DrugBank: Cefmenoxime (DB00267)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefmenoxime 3 x 1 g
Study: 6092012
Drug: mezlocillin 3
Normalized name: mezlocillin 3 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin 3 x 5 g
Study: 6092012
Drug: piperacillin 3
Normalized name: piperacillin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin 3 x 4 g
Study: 31121926
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplements (ONS) - 2 packs daily for 8 weeks
Study: 31121926
Drug: Non-Oral Nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Oral Nutritional Supplements (non-ONS)
Study: 20137063
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy (spinal manipulation/mobilization, massage, and stretching)
Study: 15640478
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (approximately 670 mg/d)
Study: 12360174
Drug: Intravenous monteplase
Normalized name: Monteplase
DrugBank: Monteplase (DB12726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous monteplase pretreatment before coronary angioplasty (Group II)
Study: 9010610
Drug: sustained-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release ibuprofen (1600 mg daily)
Study: 9010610
Drug: sustained-release diclofenac
Normalized name: diclofenac Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release diclofenac sodium (100 mg daily)
Study: 3883375
Drug: Epinephrine solution
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine solution instillation into the breast parenchyma
Study: 20735834
Drug: Thymostimulin 75
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin 75 mg s.c. 5x/week
Study: 18242365
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 300 mg/day for 32 weeks
Study: 10411795
Drug: Clomiphene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (50 mg days 5 to 9)
Study: 7756105
Drug: Amantadine HCl
Normalized name: amantadine HCl
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine HCl (3 mg kg‐1)
Study: 7014656
Drug: Propiram fumarate
Normalized name: fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiram fumarate (50 mg)
Study: 31204198
Drug: Single shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single shot of intravenous TXA 10 mg/kg
Study: 27989852
Drug: 30mg morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg morphine
Study: 18723314
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + Tipifarnib (G+t)
Study: 18723314
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + Placebo (G+p)
Study: 16702498
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel plus placebo capsules
Study: 16702498
Drug: Minocycline capsules
Normalized name: minocycline Oral Capsule
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline capsules plus vehicle gel
Study: 16702498
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel plus minocycline capsules
Study: 15611422
Drug: Oral alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin 10 mg/d
Study: 15611422
Drug: Oral alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin 20 mg/d
Study: 15611422
Drug: Oral alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin 40 mg/d
Study: 11697833
Drug: Early hyperfractionated
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early hyperfractionated thoracic radiation therapy (HTRT) concurrently with the first cycle of chemotherapy (Group A)
Study: 11697833
Drug: Late hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late hyperfractionated thoracic radiation therapy (HTRT) concurrently with the fourth cycle of chemotherapy (Group B)
Study: 9397246
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 or 10 mg)
Study: 9397246
Drug: Diltiazem (180,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180, 240, or 360 mg)
Study: 19371522
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine (10 mg)
Study: 7978566
Drug: Rectal prochlorperazine
Normalized name: prochlorperazine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal prochlorperazine (25 mg)
Study: 7978566
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine
Study: 7978566
Drug: Rectal prochlorperazine
Normalized name: prochlorperazine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal prochlorperazine
Study: 2498820
Drug: Autoinflation (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoinflation (3 times daily for 2 weeks)
Study: 31434782
Drug: SBRT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT monotherapy (40 Gy in five fractions given on alternating days)
Study: 31434782
Drug: Virtual high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual high-dose rate boost (HDRB) (20 Gy in two fractions followed by 36 Gy in 12 fractions)
Study: 28158982
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (50 micrograms daily, titrated according to TSH level)
Study: 24800335
Drug: Clean Intermittent
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean Intermittent Self Catheterisation (CISC) performed by inserting a Classic Neleton Catheter (No. 16 or 18) twice a day for 1 week, then once a day for another 4 weeks and then once weekly continued for one year.
Study: 18052950
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg per day
Study: 15254052
Drug: Irinotecan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 100 mg/m² weekly for 4 weeks followed by a 2-week rest (weekly arm)
Study: 15254052
Drug: Irinotecan 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 240 mg/m² every 3 weeks (every‐3‐weeks arm)
Study: 28960663
Drug: High-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose transdermal nicotine (90 mg/day)
Study: 25913046
Drug: Hypotonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic solution (Na 30 mEq/L NaCl or 0.18%)
Study: 25913046
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (Na 150 mEq/L or 0.9% NaCl)
Study: 25913046
Drug: Both isotonic
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both isotonic and hypotonic solutions
Study: 20653455
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications at bedtime (valsartan 160 mg/day and amlodipine 5 mg/day)
Study: 20653455
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications on awakening (valsartan 160 mg/day and amlodipine 5 mg/day)
Study: 16997056
Drug: Gentamicin/citrate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin/citrate (4 mg/mL)
Study: 9541997
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of food components and toxic compounds
Study: 8173923
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 3 micrograms kg‐1 min‐1 for 48 hours after surgery
Study: 8173923
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 3 litres 5% dextrose and bolus of intravenous frusemide 1 mg kg‐1
Study: 28833428
Drug: Feedback reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback reports containing information in combination with response certitude
Study: 25625938
Drug: D3P (docetaxel:
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3P (docetaxel: 75 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally daily)
Study: 25625938
Drug: M3P (mitoxantrone:
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3P (mitoxantrone: 12 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally daily)
Study: 1396621
Drug: Tetracycline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 mg for children, 500 mg for adults)
Study: 3530366
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (Control)
Study: 3530366
Drug: Coumarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin treatment (in limb salvage surgery)
Study: 3530366
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (Control, in limb salvage surgery)
Study: 14637276
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for 12 weeks
Study: 24047007
Drug: Intranasal pack
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pack (Group B)
Study: 12697487
Drug: Itraconazole treatment
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole treatment group
Study: 10432616
Drug: Ethanol consumption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol consumption (approximately 0.3 g/kg) as beer, white wine, or vodka mixed with orange juice
Study: 8520505
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) and total body irradiation (TBI) followed with autologous blood stem cell transplantation (ABSCT)
Study: 1722692
Drug: Mu‐cron tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mu‐cron tablets (phenylpropanolamine 50 mg)
Study: 1722692
Drug: Boots Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boots Cold Relief tablets (phenylephrine 10 mg and caffeine 60 mg)
Study: 1722692
Drug: Boots Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boots Pain Relief tablets (caffeine 60 mg)
Study: 6460717
Drug: Imipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine at 75 mg/day
Study: 6460717
Drug: Zimelidine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine at 100 mg/day
Study: 6460717
Drug: Zimelidine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine at 200 mg/day
Study: 6460717
Drug: Imipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine at 25 mg three times daily
Study: 19537838
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 or 120 mg/day
Study: 22545079
Drug: Routine 12-weekly
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine 12-weekly CD4 monitoring from year 2 on ART
Study: 9667165
Drug: Desensitizing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agents (specific agents not detailed)
Study: 2671289
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) plus Methotrexate (MTX) - CBDCA administered IV monthly at doses of 400 mg/m2, MTX given IV weekly at doses of 40 mg/m2.
Study: 2671289
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) alone - administered IV weekly at doses of 40 mg/m2.